Table 1 Characteristics of patients included in this study
Characteristics | No. of patients/No. of all patients | Percentage |
|---|---|---|
No. of patients | 7425/7425 | 100.0% |
Average Median Age (range) | 65.1 (25 to 87) | Â |
Sex | ||
 Male | 3955/6912 | 57.2% |
 Female | 2957/6912 | 42.8% |
ECOG score | ||
 0–1 | 4496/5083 | 88.5% |
 2+ | 587/5083 | 11.5% |
Site | ||
 Head or neck | 1895/4209 | 45.0% |
 Body or tail | 2037/4209 | 48.4% |
 Other* | 277/4209 | 6.6% |
Metastatic diseases | 6684/7425 | 90.0% |
Metastatic sites | ||
 Liver | 1825/3213 | 56.8% |
 Lymph nodes | 511/3213 | 15.9% |
 Peritoneal | 572/3213 | 17.8% |
 Lung | 446/3213 | 13.9% |
 Other | 401/3213 | 12.5% |
Treatments | ||
 FOLFIRINOX | 2659/6351 | 41.9% |
 GEM-NAB | 1929/6351 | 30.4% |
 GEM | 1420/6351 | 22.4% |
 mFOLFIRINOX | 343/6351 | 5.4% |